 |
Cardiology
PET imaging can play an important role
in the accurate assessment of myocardial
perfusion, free from attenuation artifacts.
PET is also the gold standard for determining
myocardial viability and suitability for
coronary intervention. |
|
Cardinal Health
PET FoundationsSM announces
a new Cardiology Module
This new Cardiology Module extends PET Foundations' education and marketing
program into the emerging area of PET imaging for heart disease management. DMS
PET
customers can access the materials that comprise this Toolkit by logging
into the PET
Foundations website and visiting the Cardiology section. |
|
|
| |
| Using PET to Access
Myocardial Viability |
| Positron Emission Tomography (PET), utilizing
18-fluorodeoxyglucose (FDG), is a well-recognized
method to assess myocardial viability. FDG
uptake equates with viability, and as many
as 30%-50% of regions felt to be scar by standard
nuclear tests are found to be viable with PET.
Additionally, categorization of myocardium
as viable versus non-viable has important prognostic
implications. The identification of viability
on the PET scan recommends revascularization,
resulting in functional as well as symptomatic
improvement in many patients |
 |
| |
| Using PET for
Myocardial Perfusion Imaging |
| Positron Emission Tomography (PET) myocardial
perfusion imaging can be performed with either
N-13 ammonia (cyclotron-produced) or rubidium-82
(generator-produced). Advantages of PET versus
SPECT include higher spatial resolution, better
attenuation correction, quantitation, true
stress function analysis, reduced radiation,
and higher accuracy. Good candidates for PET
include: patients with suboptimal SPECT or
SPECT results at odds with the clinical data,
obese patients, large breasted women, and diabetics.
Presently, PET perfusion studies are best performed
with pharmacologic stress (e.g., adenosine,
dipyridamole, or dobutamine), and can be completed
on modern PET/CT systems in less than 30 minutes. |
| |
 |
| |
|
|
|
|
